Klaus Dugi, Vandria CEO
December 2, 2025 03:00 AM EST
Updated 06:58 AM
FinancingR&D
Swiss biotech plots Series B raise to advance Alzheimer’s drug into Phase 2
Ayisha Sharma
News Reporter
Two years after coming out of stealth, Vandria said its investigational Alzheimer’s drug has shown promise in an early trial in humans …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS
Analyst – Life Sciences Strategy & Intelligence
Sedulo Group
Remote
VIEW JOB OFFER
post your job now